New antibody drug aims to tackle COVID-19 early

NCT ID NCT07156864

Not yet recruiting Disease control Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tests a new drug called B10-FC, which is a lab-made antibody designed to fight the SARS-CoV-2 virus. The study will first give the drug to 25 healthy volunteers in increasing doses to check safety, then to 10 COVID-19 patients. The main goal is to see if the drug is safe and how the body processes it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

B10-FC (a lab-made antibody designed to fight the SARS-CoV-2 virus)

What this could lead to

If successful, this could point toward a new early treatment option for COVID-19 that helps the immune system fight the virus.

What could go wrong

This is a very early Phase 1 trial with only 35 people, focused on safety and dosing. The drug may not work as hoped or could cause side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19